ESTA Establishment Labs Holdings Inc

$ESTA I’ve figured out that high gas make people think twice about buying boobs. The good news is that when the gas deflates the boobs will inflate and ESTA will become cash flow possitve. I’d love some short term pain of the 50s to grab some more.

$ESTA Establishment Labs (NASDAQ: ESTA) Buy (1) Price Target: $117.00 Positive WSEI Updates - MIS Line Extension And Tissue Preservation Evidence THE TD COWEN INSIGHT ESTA's WSEI updates earlier this week reinforced our positive views on the company's MIS platform as meaningful Mia / Preservé size expansions could catalyze increased demand. Additionally, newly published Breast Tissue Preservation data strengthens the case that ESTA is building a differentiated augmentation paradigm with disruptive MIS implant placement techniques. Reiterate Buy.

$ESTA What’s up with the weird premarket and after hours price differences? Two days ago after hours was 13% up now today premarket 8% up

$ESTA purchased a bit more this morning. Will continue to DCA. Starting to build a very large position here. Not my #1, but quickly will become it if it remains here. Interest rate impacting anything financable I imagine.

$ESTA Establishment Labs (NASDAQ: ESTA) Buy (1) Price Target: $117.00 FDA Approval of Smaller Round/Ergo Implant Lines Adds Another Growth Lever THE TD COWEN INSIGHT This morning, ESTA announced FDA approval of multiple lines of smaller Motiva and Ergonomix implant sizes, expanding access for patients seeking more subtle enhancement and potentially representing a modest 4Q upside driver. During our Plastic Surgeon Roundtable (report here), surgeons highlighted meaningful demand for these sizes, consistent with the view that they expand ESTA's U.S. TAM by ~10%.

$ESTA Establishment Labs (NASDAQ: ESTA) Buy (1) Price Target: $117.00 Plastic Surgeon Roundtable: Motiva Share Gains Meet Preservé Market Expansion THE TD COWEN INSIGHT Our latest KOL roundtable, featuring 3 high-volume plastic surgeons (2 of whom have undergone Motiva and Preservé, respectively), reinforced our view that ESTA's innovation cycle is expanding the breast aesthetics market. Surgeons reported near-exclusive use of Motiva, exceptionally high Preservé uptake among eligible patients, meaningful pricing power, and growing enthusiasm for Mia and Ergo 2.

$ESTA downside possibility to the 53 range, where the weekly 200 sits. Dont like the break of 70 but, is what it is. Looking to add mid 60s, definitely at the low 50s if we get there. Recon indication was approved today, would expect this to be positively reflected soon.

$ESTA damn, even HCG 👇🏻 decided to join the party. He’s not always the best indicator, but it’s usually positive